Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for awake bruxism
RBR-97n3sgvPhase 2Not yet recruiting
- Sponsor
- Departamento de Odontologia
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial in Awake Bruxism (AB) comparing Cannabidiol + behavioral management with Placebo + behavioral management (2 arms). Primary endpoint: Frequency of awake bruxism. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
Awake Bruxism (AB)
Beyond the preview
Go deeper on RBR-97n3sgv.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-97n3sgv.